TEL: 044-952-0102

多発性硬化症 (MS)

Multiple Sclerosis [2017]

発行 FirstWord 商品コード 593145
出版日 ページ情報 英文
納期: 即日から翌営業日
本日の銀行送金レート: 1USD=108.52円で換算しております。
Back to Top
多発性硬化症 (MS) Multiple Sclerosis [2017]
出版日: 2017年11月01日 ページ情報: 英文

当レポートでは、多発性硬化症 (MS) 治療薬について調査分析し、上市薬・パイプライン薬に焦点を当てて、米国と欧州のKOL12名による見解について、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査目的

第3章 調査の焦点

第4章 上市済み治療薬

  • 概要
    • Interferon beta
    • Copaxone
    • Tecfidera
    • Aubagio
    • Gilenya
    • Tysabri
    • Lemtrada
    • Zinbryta
    • Ocrevus
    • Mavenclad

第5章 パイプライン治療薬

  • 概要
    • Ofatumumab
    • Biotin
    • Sphingosine modulators
    • ALKS 8700
    • Nerventra

第6章 MSの初期段階の開発

第7章 現在・将来の治療アルゴリズム

第8章 付録


How will Ocrevus reshape the MS treatment landscape?

A multitude of recent approvals and launches are changing the way MS is treated, but what does the future hold? Key opinion leaders (KOLs) are excited about Ocrevus' approval in relapsing and progressive forms of the disease and Mavenclad's European approval gives patients another treatment choice, but which therapy will stand out in an evolving and competitive landscape? Other disease modifying therapies are in late-stage development but which segment of the market can they expect to capture? Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in KOL Insight: Multiple Sclerosis. Twelve of the world's most prominent KOLs provide their candid insights on ten marketed products and seven Phase III pipeline programmes.

Download sample pages

Plus: Order the report and you'll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Take a tour of the report now

  • The table of contents >
  • The key business questions answered >
  • The key KOL quotes >
  • See the therapies covered >
  • Find out who the 6 EU & 6 US KOLs are >
  • Review an extract from the report - 1 drug profile >

Top takeaways

  • How is Ocrevus expected to fare? With approval in RRMS and PPMS, how will this new therapy be prescribed and against which products will it compete?
  • Are the new sphingosine modulators set to compete with Gilenya? With ozanimod and ponesimod both undergoing Phase III evaluation, find out how KOLs view these agents.
  • Is ofatumumab considered a real threat to Ocrevus or a 'me-too' drug? Do KOLs see any potential advantages, or is it too late to the game?
  • Where will Mavanclad be positioned in the treatment paradigm? This therapy received EU approval as a treatment for highly active relapsing MS, but how do KOLs envision prescribing it?
  • What factors will be important in determining biotin's (MD-1003) future success?Pharmaceutical-grade biotin is undergoing regulatory review in Europe as a potential therapy for progressive MS, but what will need to be addressed in order to secure commercial success?
  • To what extent will oral disease-modifying therapies be prescribed in the future? Find out whether KOLs think these agents' market share will increase, decrease or stay stable in the near future?
  • How are interferon beta products currently being prescribed? Has there been a shift in interferon beta prescribing and how do KOLs envision their use in the future?
  • What does the future hold for Copaxone as a therapy for MS? Find out KOLs' thoughts on how this drug will be prescribed in the future and what impact a thrice-weekly generic is expected to have.

Request sample pages

Back to the top


"I expect a trial [of ofatumumab] in progressive disease. As a clinical scientist, I would love to see confirmation of the ORATORIO data with a similar or identical approach. I understand that the company is still deliberating on this."EU Key Opinion Leader

"We are currently using Ocrevus second-line, but in some cases first-line too. We have no barriers to prescribing, not from my standpoint. Finding infusion chairs is improving. I don't know that there are any big reimbursement issues, although I think it's an evolving story."North American Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Interferon beta products (Biogen/Merck Serono/EMD Serono/Bayer/Novartis)
  • Copaxone (glatiramer acetate; Teva)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Aubagio (teriflunomide; Sanofi/Genzyme)
  • Gilenya (fingolimod; Novartis)
  • Tysabri (natalizumab; Biogen)
  • Lemtrada (alemtuzumab; Sanofi)
  • Zinbryta (daclizumab; Biogen/AbbVie)
  • Ocrevus (ocrelizumab; Roche/Biogen)
  • Mavenclad (cladribine; Merck Group)

Pipeline Therapies

  • ofatumumab (Novartis/Genmab)
  • biotin (MD1003; MedDay/Medical Need)
  • ozanimod (RPC 1063; Celgene)
  • siponimod (BAF 312; Novartis)
  • ponesimod (ACT 128800; Actelion)
  • ALKS 8700 (Alkermes)
  • laquinimod (Nerventra; Active Biotech/Teva)

KOLs interviewed

KOLs from North America

  • Prof Mark Freedman, MD, Professor of Medicine in the field of neurology at the University of Ottawa and Director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus, Ottawa, Ontario, Canada.
  • Prof Shiv Saidha, MD, MBBCh, Associate Professor of Neurology at Johns Hopkins Medicine, Baltimore, MD, USA.
  • Prof David Hafler, MD, William S. and Lois Stiles Edgerly Professor and Chairman of Neurology, Yale School of Medicine and the Neurologist-in-Chief of the Yale-New Haven Hospital, CT, USA.
  • Prof Bianca Weinstock-Guttman, MD, Professor of Neurology and Director of the Jacobs Multiple Sclerosis Center for Treatment and Research, University at Buffalo (SUNY), NY, USA.
  • Prof Rob Naismith, MD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, MO, USA.
  • Prof Aaron Miller, MD, Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis & Professor and Vice-Chair for Education, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.

KOLs from Europe

  • Prof Patrick Vermersch, MD, Professor of Neurology at Clinique Neurologique, Centre Hospitalier Regional Universitaire de Lille, Centre de Biologie Pathologie Genetique Lille, France.
  • Prof Celia Oreja-Guevara, MD, Chair of Clinical Research, Multiple Sclerosis Unit, Department of Neurology, IdISSC, University Hospital San Carlos, Madrid, Spain.
  • Prof Oscar Fernandez, MD, Professor, Medical Neurologist and Senior Investigator at the Hospital Universitario Virgen de la Victoria, Malaga, Spain.
  • Prof Daniel Guillaume, MD, Neurologist and Medical Director of the Centre Neurologique et de Readaptation Fonctionnelle, Fraiture en Condroz, Belgium.
  • Anonymous, German KOL, Professor of Neurology at a leading German university hospital.
  • Anonymous, German KOL, Professor of Neurology at a leading German university hospital.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Table of Contents

1. Executive summary

2. Research objectives

3. Research focus

4. Marketed drugs

  • 4.1 Overview
    • 4.1.1 Interferon beta
    • 4.1.2 Copaxone (glatiramer acetate; Teva)
    • 4.1.3 Tecfidera (dimethyl fumarate; Biogen)
    • 4.1.4 Aubagio (teriflunomide; Sanofi)
    • 4.1.5 Gilenya (fingolimod; Novartis)
    • 4.1.6 Tysabri (natalizumab; Biogen)
    • 4.1.7 Lemtrada (alemtuzumab; Sanofi)
    • 4.1.8 Zinbryta (daclizumab; Biogen/AbbVie)
    • 4.1.9 Ocrevus (ocrelizumab; Roche/Biogen)
    • 4.1.10 Mavenclad (cladribine; Merck Group)

5. Pipeline drugs

  • 5.1 Overview
    • 5.1.1 Ofatumumab (Novartis/Genmab)
    • 5.1.2 Biotin (MD1003; MedDay/Medical Need)
    • 5.1.3 Sphingosine modulators
    • 5.1.4 ALKS 8700 (Alkermes)
    • 5.1.5 Nerventra (laquinimod; Active Biotech/Teva)

6. Earlier-stage developments in MS

7. Current and future treatment algorithm

8. Appendix

  • 8.1 KOL details
    • 8.1.1 KOLs from North America
    • 8.1.2 KOLs from the EU
Back to Top